Speakers

Expand/Collapse

Jonah Rainey, PhD
VP of Antibody Engineering and Protein Science
AlivaMab Discovery Services

Track A - Day 1 AM

11:45 am | Session Reserved for Discovery

Daniel Bedinger
Application Science Manager
Carterra

Track B Day 2 AM

11:00 am | High throughput SPR characterization of multi-specific antibodies. Capabilities and workflow approaches advancing discovery

Giorgio Salciarini
Marketing & Business Development Manager
BSP

Day One

Wednesday, September 21 | 2022

9:00 am | Looking to Satisfy the Growing Demand of Capacity and Capabilities for Biologics

Alexander Haas
Head Biologics Core Technologies
Roche

Track B Day 2 PM

1:30 pm | Graphical Design, Engineering & In Silico Cloning of Multispecific Antibodies

Aman Singh
Associate Director, Cell Therapy Clinical Pharmacology, Modeling & Bioinformatics
Takeda

Track A Day 2 AM

11:00 am | Translational PK/PD Investigations & Multiscale Mechanism-Based Modeling to Support Development of T Cell Redirecting Antibodies

Ankita Srivastava
Vice President - Protein Sciences & Rational Design
Ichnos Sciences

Track B Day 2 PM

2:00 pm | TREAT 2.0: A Versatile Platform Technology for Development of Multispecific Antibodies

Anthony Stein
Medical Doctor
City of Hope

Day Two

Thursday, September 22 | 2022

4:00 pm | Improving Bispecific Antibody Outcome in Acute Myeloid Leukemia

Azra Mujic-Delic
Principal Scientist - Functional Characterization & Bioassays
Genmab

Track B Day 2 AM

11:30 am | Potency Assay Strategy from Early to Late Clinical Development: A Bispecifics Case Study

Brandon Leonard
Principal Scientific Researcher - Antibody Engineering
Genentech

Track B Day 2 PM

2:30 pm | Leveraging Homotypic Antibody Interfaces for Biotherapeutic Engineering

Colette Johnston
Vice President Discovery
Crescendo Biologics

Day One

Wednesday, September 21 | 2022

4:15 pm | CB307: A Novel T Cell Costimulatory Humabody VH Therapeutic for PSMA-Positive Tumors

Chava Kimchi-Sarfaty
Deputy Associate Director - Research Office of Tissue & Advanced Therapies
CBER, FDA

Track B - Day 1 PM

2:15 pm | VIRTUAL: Exploring the Consequences of Codon Optimization on Therapeutic Sequences

Christopher Mehlin
Chief Scientific Officer & Co-founder
Link Immunotherapeutics

Day One

Wednesday, September 21 | 2022

9:10 am | Panel Discussion – CAR T vs. Multispecifics

Focus Day Track A - PM

2:00 pm | Roundtable Discussion - Understanding Different Formats Behavior to Identify Which One Works Best

Daniel Pereira
Chief Scientific Officer
Invenra

Day Two

Thursday, September 22 | 2022

8:50 am | Uncovering the Therapeutic Potential of a Next Generation Tumor Treg Deplete

David Poon
Vice President – Business Development & Alliance Management
Zymeworks

Track A - Day 1 PM

2:15 pm | Expanding the Therapeutic Window for Immune- Engaging Multi-Specifics Through Conditional Activation & Co-Stimulation

Diego Ellerman
Principal Scientific Researcher
Genentech

Track A - Day 1 PM

1:15 pm | CLEC5a-Directed Bispecific Antibody for Effective Cellular Phagocytosis

Erin Meermeier
Research Associate Scientist - Division of Hematology and Oncology
Mayo Clinic

Focus Day Track A - AM

11:00 am | Evaluating Novel formats & Testing Efficacy in Fully Immunosufficient in vivo Models

Eugene Zhukovsky
Chief Scientific Officer
Ichnos Sciences

Day One

Wednesday, September 21 | 2022

9:10 am | Panel Discussion – CAR T vs. Multispecifics

Ezio Bonvini
Chief Scientific Officer
Macrogenics

Track A Day 2 PM

2:00 pm | Overcoming the Challenges of a First-Generation CD123-Directed Bispecific CD3-Engaging DART Molecule

Harald Kolmar
Department Head Applied Biochemistry
Technical University of Darmstadt

Focus Day Track A - AM

10:30 am | A Productive Relationship for NK Cell Engagement: Multispecific Two-In-One Antibodies

Jeffrey Way
Lecturer - Department of Systems Biology
Harvard Medical School

Track B - Day 1 PM

2:45 pm | Rational Engineering of an Erythropoietin Fusion Protein to Treat Hypoxia”

Jonathan Davis
Vice President - Innovation and Strategy
Invenra

Track B - Day 1 PM

1:45 pm | Correlating Multispecific Structures to their Functions for a Holistic Overview of Product Design

Julia Frei
Principal Scientist
Ichnos Sciences

Track B - Day 1 PM

1:15 pm | ISB 1442, a First-in-Class 2+1 Fc Engineered Biparatopic Bispecific BEAT® 2.0 antibody targeting CD38 and CD47

Kalyan Pande
Associate Principal Scientist – Protein Engineering & Modalities
Merck

Focus Day Track A - PM

1:30 pm | Multimerization of Single-Domain Antibodies Targeting Viral Glycoproteins for Enhanced Potency

Liqin Liu
Senior Director of T Cell Engagers
IGM Biosciences

Focus Day Track B - AM

11:30 am | IGM-2323 - High Avidity IgM-Based CD20xCD3 Bispecific Antibody for Enhanced T Cell Dependent Killing with Minimal Cytokine Release

Martin Siegemund
Senior Scientist
Pieris Pharmaceuticals

Focus Day Track A - AM

11:30 am | Anticalin Proteins as Key Components in Advanced Multispecific Formats

Nimish Gera
Vice President - Biologics Research
Mythic Therapeutics

Focus Day Track B - PM

1:30 pm | Roundtable Discussion - Evaluating Tumor Toxicity for Immune Cell Re-Targeting

Pranjali Dalvi
Senior Scientist
Amgen

Track A Day 2 PM

1:30 pm | Decoupling Cytotoxicity with Cytokine Release: Development of Safe CD3 T Cell Engagers for Solid Tumors

Prathap Shastri
Scientific Director, DMPK, Preclinical Sciences and Translational Safety
Johnson & Johnson

Day Two

Thursday, September 22 | 2022

4:30 pm | Panel Discussion - Unlocking the Potential of Combinatorial Strategies of Bispecifics in a Clinical Setting

Track A - Day 1 PM

2:45 pm | Retrospective Look at Translational Considerations & FIH Dosing Approaches for T-cell Redirectors

Rakesh Dixit
President and Head of R&D, Co-Founder
Regio Biosciences

Track A - Day 1 AM

10:45 am | On and Off-Target Toxicities of Bispecific Targeted Biologics: Mitigation Strategies

Shailee Patel
Researcher
Beacon Targeted Therapeutics

Day One

Wednesday, September 21 | 2022

8:30 am | The Landscape of Bi/Multispecifics

Shaun Lippow
Vice President, Drug Discovery & Protein Engineering
Atreca

Track B - Day 1 AM

10:45 am | Engineering Safe & Effective Bispecific Immunotherapies for Solid Tumor Indications

Suzanne Schubbert
Associate Director - Discovery Biology & Pharmacology
Xencor

Focus Day Track B - PM

1:00 pm | LAG3-Targeted IL15/IL15Rα-Fc (LAG3 x IL15) Fusion Protein for Preferential TIL Expansion

Vera Sellers
Associate Director - Molecule Group, Protein & Cell Sciences Discovery & Development Technologies
EMD Serono

Track A - Day 1 AM

11:15 am | Early Developability of Multispecifics

Wadim Matochko
Scientist Antibody Discovery
Amgen

Track B - Day 1 AM

11:15 am | Target Biology & Antibody Attributes Drive Multispecific Format Selection & Engineering

Wei Yan
President & Chief Executive Officer
Sound Biologics

Focus Day Track B - AM

11:00 am | Rationale Design of the Next Generation Bifunctional Checkpoint Inhibitors

Werner Meier
Chief Scientific Officer
Revitope Oncology

Day Two

Thursday, September 22 | 2022

9:30 am | Guided Antibody Tumor Engagers (TwoGATE™), a Sophisticated & Differentiated Approach for T Cell Redirection in Solid Tumors

Yanchen Zhou
Principle Scientist
Amgen

Focus Day Track A - PM

1:00 pm | VIRTUAL: Understanding the Pre-Existing Reactivity of BsAbs for Mitigation Strategies

John Burke
Co-Founder, President & Chief Executive Officer
Applied BioMath

Musheng Bao
Senior Director, Discovery Oncology
Harbour Biomed

Track A Day 2 PM

2:30 pm | Generation of Innovative B7H4 x CD3 & B7H4 x 4-1BB Bispecifics for Solid Tumor Therapies

Christel Iffland, PhD.
VP, Antibody Technology
OmniAb, Inc.

Track B - Day 1 AM

11:45 am | High Specificity OmniAb Antibodies for Bispecific Applications

Alexander Schinagl
Chief Technology Officer
OncoOne

Track A Day 2 AM

11:30 am | PreTarg-it®: A modular platform utilizing bispecific antibodies for optimized biodelivery of payloads.

John Burke, PhD
Co-Founder, President, and CEO
Applied BioMath

Track B Day 2 AM

12:00 pm | Model-Informed Drug Discovery & Development Aids in the Design & Dose Prediction for Multispecific Therapeutics

Ken Howard
Associate Professor and Group Leader
Aarhus University

Focus Day Track B - AM

10:30 am | Programmable Half-Life & Anti-Tumour Effects of Bi-Specific T-Cell Engager-Albumin Fusions with Tuned FcRn Affinity

Laura von Schantz
Vice President Discovery
Alligator Bioscience

Day One

Wednesday, September 21 | 2022

9:10 am | Panel Discussion – CAR T vs. Multispecifics

Day Two

Thursday, September 22 | 2022

4:30 pm | Panel Discussion - Unlocking the Potential of Combinatorial Strategies of Bispecifics in a Clinical Setting

Track A - Day 1 PM

1:45 pm | Kick-Starting Tumor Specific T Cell Cross-Priming Using Neo-X-Prime Bispecific Antibodies Targeting CD40

Your 2022 Expert Speakers